FDA Approves Zuranolone for Postpartum Depression : vimarsan

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

Related Keywords

United States , American , Sagarv Parikh , Andrewj Cutler , Anita Clayton , Wilfordw Spradlin , Kuntzl Zuranolone , Johnf Greden , Kunzmannk Zuranolone , Beth Israel Lahey Health , University Of Virginia School Medicine , Drug Administration , Postpartum Depression In Clinical Program , Hcplive Peer Exchange , Biogen Inc , American Psychiatric Association , Sage Therapeutics , Hamilton Depression Rating Scale , New Orleans , Virginia School , Peer Exchange , Clinical Neuroscience , Mount Auburn Hospital , First Oral Treatment , New Data Presented , American College , Published December , Biogen Announce , Postpartum Depression Met , All Key Secondary , Benefits Major Depression , Postpartum Depression , Published May , Zuranolone Use , Published January , Zuranolone , Major Depressive Disorder , Mmdd , Depression , Ppd , Fda , Sage , Biogen ,